Test Menu
Statistically, 40% of the US patient population will have some form of cardiovascular disease by 2030. How are you currently assessing your patients for their cardiovascular risk?
Confidence for You
With your hectic day, you don’t have the luxury of time. Aviir makes is easy for you to put together the pieces of your patient’s overall cardiovascular health picture, starting with test results you can use with confidence to manage this growing segment of patients.
Our CLIA-certified laboratory provides an extensive menu of standard of care tests for wellness assessment that includes:
- Metabolic system (both basic and comprehensive)
- Thyroid function (with thyroid cascade)
- Lipid, renal, hepatic & electrolyte panels (along with other individual tests)
- Cardiac function (including Framingham Risk Score Calculation)
For a full listing of the Standard Cardiac and Metabolic Tests, click here.
For additional information on ordering tests and specimen collection options, click here.
Convenience for Your Patients
Your patients are busy, too. They don’t have time to wait in line at busy drawing stations or put up with inexperienced staff drawing their blood sample. Aviir offers the ultimate convenience through our unique Concierge Phlebotomy Services ideal for ALL of your patients … not just those that are home-bound. An experienced, professional phlebotomist goes to the patient’s home or office to draw the blood sample – doing it right the first time.
To schedule a patient blood draw appointment with our Concierge Phlebotomy Service, click here.
Redefining the Status Quo to Reveal True Cardiovascular Risk
While a Framingham or similar score is recommended as the basic risk assessment for asymptomatic adult patients, additional risk markers should also be used to improve risk assessment according to the American Heart Association. In particular, it is recommended that intermediate risk individuals need additional testing to further define risk status. With no specific treatment recommendations for this group, highly variable treatment approaches are used. So, many patients in this group may be under-treated.
Aviir introduces the TruRisk™ assessment to address this clinical need – the objective choice to assess cardiovascular risk in patients between 40 and 80 years old that are classified at intermediate risk by traditional risk factors. TruRisk is an exclusive, novel blood-based assessment that aids in further defining the intermediate risk patient group. The test objectively reclassifies those patients that are actually high risk with an absolute 5-year risk score.
To learn more about how the Aviir TruRisk™ assessment helps you manage your patients cardiovascular risk status, click here.
